New drug combo may keep severe colitis patients out of the hospital
NCT ID NCT07258771
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether adding upadacitinib (Rinvoq) to standard steroid treatment helps people with a severe ulcerative colitis flare-up recover faster and avoid emergency care or surgery. About 110 adults with acute severe ulcerative colitis will be randomly assigned to get either steroids alone or steroids plus upadacitinib. The main goal is to see if more people in the combo group have a quick improvement within 5 days.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- upadacitinib (Rinvoq) and methylprednisolone (Solumedrol)
- What this could lead to
- If it works, this could offer a faster, more effective way to control severe flare-ups and reduce the need for emergency hospital stays or surgery.
- What could go wrong
- This is a single-center, early-phase trial with only 110 participants, so results may not apply broadly. Upadacitinib also carries risks like infection and blood clots.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ULCERATIVE COLITIS ACUTE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
University of Michigan
RECRUITINGAnn Arbor, Michigan, 48109, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.